Jimu News.
Today (December 13), the National Health Insurance Administration held a press conference to announce the results of the adjustment of the 2023 National Medical Insurance Drug List. The new version of the National Medical Insurance Drug List has a total of 3,088 drugs and will be implemented from January 1, 2024.
This year is the sixth consecutive year that the National Medical Insurance Drug List has been adjusted, and after the corresponding proceduresA total of 126 drugs have been added to the National Medical Insurance Drug List, and 1 drug has been transferred out of the List。In the negotiation and bidding process, 143 out-of-catalogue drugs participated, of which 121 were successful in negotiation or bidding, with a success rate of 846%，The average price reduction is 617%，Both the success rate and the ** drop are about the same as in 2022. Overlapping negotiated price reductions and medical insurance reimbursement factors,It is expected to reduce the burden on patients by more than 40 billion yuan in the next two years。Among the new drugs, there are 21 kinds of drugs for tumors, 17 kinds of drugs for new crown and anti-infective, 15 kinds of drugs for chronic diseases such as diabetes, psychiatry, rheumatism and immunity, 15 kinds of drugs for rare diseases (among which avatinib tablets are also drugs for tumors), and 59 kinds of drugs used in other fields. After this round of adjustments,The total number of drugs in the National Medical Insurance Drug List has reached 3,088, including 1,698 kinds of Western medicines and 1,390 kinds of Chinese patent medicines;There are still 892 kinds of Chinese medicine decoction pieces. The level of protection in the fields of chronic diseases, rare diseases, and children's medication has been further improved. Since its establishment, the National Health Insurance Administration has carried out the adjustment of the drug catalogue for six consecutive years, adding a total of 744 drugs to the national medical insurance drug catalogue, and at the same time transferring a number of drugs with uncertain efficacy, clinical abuse or obsolescence out of the catalogue. The relevant statistics of the Chinese Pharmaceutical Association show that since 2018, the proportion of medical insurance drugs in the use of drugs in medical institutions has increased year by year, the dominant position has been further consolidated, and the rationality of clinical drug use has been actively improved. At the same time,The speed of innovative drugs entering the medical insurance has been significantly accelerated, and the level of commonly used drugs** has decreased significantlyThe level of drug protection for major diseases and special groups has been greatly improved, and the burden of drug use on the masses has been significantly reduced. **Hubei release, news broadcast, Wuhan release.
Editor: Huang Lin.
Review: Xie Likui.